ClinicalTrials.gg
CompletedNCT01415778Updated May 30, 2012

Bioequivalence of ICI176,334-1 in Japanese Healthy Male Subjects

A Phase 1 interventional study of ICI176,334-1 and Casodex 80 mg tablet in Healthy, sponsored by AstraZeneca. Completed. Open to male participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-05-30.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
20 Years to 45 Years
Sex
Male
01

Study summary

The purpose of this study is to investigate the bioequivalence of ICI176,334-1 in Japanese healthy male subjects.

Read the detailed description

Bioequivalence study of ICI176,334-1 in Japanese healthy male subjects - evaluation of bioequivalence of ICI176,334-1 and Casodex 80 mg tablet -

02

Conditions studied

  • Healthy

Keywords

  • Bioequivalence
  • pharmacokinetics
  • safety
  • bicalutamide
  • Casodex
  • Japanese
  • healthy subject
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed and dated, written prior to any study specific procedures
  • Japanese healthy male subjects aged 20 to 45 years
  • Male subjects should be willing to use barrier ie, condoms, until 3 months after the last dose of product
  • Have a (BMI) between 17 and 27 kg/m2
  • Eligible based on the physical findings, supine BP, pulse rate, and laboratory assessments, as judged by the investigator(s)

Exclusion criteria

Exclusion Criteria:

  • Presence of any disease under medical treatment
  • History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, immunological, blood, endocrine, neurological or mental disease to interfere with absorption, distribution, metabolism or excretion of drugs judged by investigator(s)
  • Presence of any infectious disease, such as bacteria, virus and fungus
  • Presence of allergic disorder, such as asthma, pollen disease or atopic dermatitis, and judged as necessary any medical treatment
  • Any large surgical history of gastrointestinal tract such as gastric/intestinal resection or suturation
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Active 1

    12 subjects will receive ICI176,334-1 and Casodex 80 mg tablet

    Drug: ICI176,334-1 · Drug: Casodex 80 mg tablet

  • Experimental
    Active 2

    12 subjects will receive ICI176,334-1 and Casodex 80 mg tablet

    Drug: ICI176,334-1 · Drug: Casodex 80 mg tablet

  • Experimental
    Active 3

    12 subjects will receive ICI176,334-1 and Casodex 80 mg tablet

    Drug: ICI176,334-1 · Drug: Casodex 80 mg tablet

  • Experimental
    Active 4

    12 subjects will receive ICI176,334-1 and Casodex 80 mg tablet

    Drug: ICI176,334-1 · Drug: Casodex 80 mg tablet

Interventions

06

What researchers measure

Primary outcomes

  1. To investigate the bioequivalence of ICI176,334-1 by assessment of maximum plasma concentration (Cmax)

    Time frame: Blood samples are taken repeatedly for 72 hours and also taken occasionally up to 672 hours after each dose period

  2. To investigate the bioequivalence of ICI176,334-1 by assessment of time to Cmax (tmax)

    Time frame: Blood samples are taken repeatedly for 72 hours and also taken occasionally up to 672 hours after each dose period

  3. To investigate the bioequivalence of ICI176,334-1 by assessment of area under the plasma concentration curve (AUC)

    Time frame: Blood samples are taken repeatedly for 72 hours and also taken occasionally up to 672 hours after each dose period

  4. To investigate the bioequivalence of ICI176,334-1 by assessment of t1/2 of bicalutamide

    Time frame: Blood samples are taken repeatedly for 72 hours and also taken occasionally up to 672 hours after each dose period

Secondary outcomes

  1. To assess the safety by assessment of adverse event

    Time frame: Screening day up to 35 to 42 days (follow-up)

  2. To assess the safety by assessment of vital signs

    Time frame: Collect prior to treatment and up to 35 to 42 days (follow-up) after the last dose.

  3. To assess the safety by assessment of electrocardiograms (ECGs)

    Time frame: Collect prior to treatment and up to 35 to 42 days (follow-up) after the last dose.

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2011, a primary completion of Nov 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2011
First posted
Aug 12, 2011
Start
Aug 2011
Primary completionActual
Nov 2011
CompletionActual
Dec 2011
Last update
May 30, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01415778
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Aug 12, 2011
Start date
Aug 2011
Primary completion
Nov 2011
Completion
Dec 2011
Last update
May 30, 2012
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bicalutamide

Start the discussion